IDACIO
Live · Registered LIVE/REGISTRATION/Issued and Active
What this record means
The record shows that the mark IDACIO is live and registered on the Principal Register, with Fresenius Kabi Deutschland GmbH listed as the owner. It covers pharmaceutical preparations for human use, specifically treatments for neurological, immunological, inflammatory, oncological and viral conditions, as well as a range of autoimmune and inflammatory disorders such as plaque psoriasis, rheumatoid arthritis and Crohn’s disease. Because the listed goods are narrowly focused on medical drugs, a similar name used for unrelated products would be a farther concern, but a comparable name in the pharmaceutical field would present the closest record‑based risk. The record does not give the owner control over every possible use of the word “IDACIO.” The most recent meaningful event is the registration date of September 26 2023, and the supplied history shows no oppositions, cancellations or other enforcement activity. I'd treat this as a meaningful concern if you plan a pharma‑related brand using a similar name.
Informational only - not legal advice.Mark Trademark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Use in Commerce (§1(a)). |
| Status | Registered. The registration date is used to determine when post-registration maintenance documents are due. |
Key dates
| Application filed | Apr 21, 2022 |
| Published for opposition | Nov 22, 2022 |
| Notice of Allowance | Jan 17, 2023 |
| Registered (Principal) | Sep 26, 2023 |
| Status date | Sep 26, 2023 |
Goods & services
Pharmaceutical preparations for human use for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Pharmaceutical preparations, namely, immunosuppressants; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and active enthesitis related arthritis, Crohn's disease, ulcerative colitis, hidradenitis colitis, hidradenitis suppurativa and non-infectious uveitis; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Biologics, namely, biological preparations for the treatment of neurological diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, oncological diseases and disorders and viral infections; Biologics, namely, biological preparations for the treatment of ankylosing spondylitis; Biological preparations for the treatment of and reducing signs and symptoms in adult patients with active ankylosing spondylitis; Protein therapeutics, namely, protein supplements; Pharmaceutical preparations for treating ankylosing spondylitis; Pharmaceutical preparations for the treatment of and for reducing signs and symptoms in adult patients with active ankylosing spondylitis; Pharmaceutical preparations for treating a wide variety of autoimmune diseases, illnesses and conditions
Owner & representation
| Owner | Fresenius Kabi Deutschland GmbH |
| Address | Else-Kroener-Str. 1, Bad Homburg GERMANY 61352 |
| Entity | LIMITED LIABILITY COMPANY - organized in GERMANY |
| Attorney of record | Scott D. Woldow |
| Correspondent | Scott D. Woldow |
| Attorney email | s********@*****.com |
| Correspondent email | 2 emails |
| Correspondent phone | 2********0 |
| Correspondent address | WASHINGTON, DISTRICT |